JP2022523368A5 - - Google Patents
Info
- Publication number
- JP2022523368A5 JP2022523368A5 JP2021549407A JP2021549407A JP2022523368A5 JP 2022523368 A5 JP2022523368 A5 JP 2022523368A5 JP 2021549407 A JP2021549407 A JP 2021549407A JP 2021549407 A JP2021549407 A JP 2021549407A JP 2022523368 A5 JP2022523368 A5 JP 2022523368A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- temperature
- syndrome
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019075834 | 2019-02-22 | ||
| CNPCT/CN2019/075834 | 2019-02-22 | ||
| PCT/EP2020/054485 WO2020169736A1 (en) | 2019-02-22 | 2020-02-20 | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523368A JP2022523368A (ja) | 2022-04-22 |
| JP2022523368A5 true JP2022523368A5 (cg-RX-API-DMAC7.html) | 2023-02-28 |
Family
ID=69723907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549407A Pending JP2022523368A (ja) | 2019-02-22 | 2020-02-20 | 1-(1-オキソ-1,2-ジヒドロイソキノリン-5-イル)-5-(トリフルオロメチル)-n-[2-(トリフルオロメチル)ピリジン-4-イル]-1h-ピラゾール-4-カルボキサミド一水和物の結晶形態 |
Country Status (21)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| JP2023539729A (ja) | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ.ベー. | Malt1阻害剤の非晶質形態及びその製剤 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| KR20230154227A (ko) | 2021-03-03 | 2023-11-07 | 얀센 파마슈티카 엔브이 | 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 |
| WO2023016995A1 (en) | 2021-08-09 | 2023-02-16 | Janssen Pharmaceutica Nv | Compositions for use in treating b-cell malignancies |
| AU2024357109A1 (en) | 2023-10-06 | 2026-03-12 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1622571A4 (en) | 2003-04-30 | 2012-05-02 | Agensys Inc | NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 109P1D4 FOR THE TREATMENT AND DETECTION OF CANCER |
| KR20090007347A (ko) * | 2006-03-22 | 2009-01-16 | 버텍스 파마슈티칼스 인코포레이티드 | 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제 |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| WO2011036885A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| WO2011161612A1 (en) | 2010-06-22 | 2011-12-29 | Basf Se | Process for preparing 4-hydroxypyridines |
| JP6231085B2 (ja) * | 2012-05-31 | 2017-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アミノキナゾリン誘導体及びピリドピリミジン誘導体 |
| JP6545197B2 (ja) | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用 |
| MX2017001656A (es) | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
| US10835524B2 (en) * | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
| EP3374361A1 (en) | 2015-11-13 | 2018-09-19 | Novartis AG | Novel pyrazolo pyrimidine derivatives |
| WO2017151786A1 (en) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| TWI795381B (zh) * | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
| EP3576744A1 (en) | 2017-02-01 | 2019-12-11 | Medivir Aktiebolag | Therapeutic applications of malt1 inhibitors |
| KR20200105678A (ko) | 2017-12-28 | 2020-09-08 | 더 제너럴 하스피탈 코포레이션 | Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함 |
| EP3756268A1 (de) | 2018-02-23 | 2020-12-30 | Industrieanlagen-Betriebsgesellschaft mbH | Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| JP2023539729A (ja) * | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ.ベー. | Malt1阻害剤の非晶質形態及びその製剤 |
-
2020
- 2020-02-20 BR BR112021016400-6A patent/BR112021016400A2/pt not_active Application Discontinuation
- 2020-02-20 EP EP20707585.4A patent/EP3927696B1/en active Active
- 2020-02-20 JP JP2021549407A patent/JP2022523368A/ja active Pending
- 2020-02-20 CA CA3129623A patent/CA3129623A1/en active Pending
- 2020-02-20 SG SG11202108909SA patent/SG11202108909SA/en unknown
- 2020-02-20 KR KR1020217029765A patent/KR20210131371A/ko not_active Withdrawn
- 2020-02-20 MX MX2021010133A patent/MX2021010133A/es unknown
- 2020-02-20 EA EA202192320A patent/EA202192320A1/ru unknown
- 2020-02-20 US US17/431,447 patent/US12269813B2/en active Active
- 2020-02-20 MA MA055019A patent/MA55019A/fr unknown
- 2020-02-20 WO PCT/EP2020/054485 patent/WO2020169736A1/en not_active Ceased
- 2020-02-20 PE PE2021001372A patent/PE20212067A1/es unknown
- 2020-02-20 ES ES20707585T patent/ES2966132T3/es active Active
- 2020-02-20 CN CN202080015968.5A patent/CN113474339B/zh active Active
- 2020-02-20 AU AU2020226723A patent/AU2020226723B2/en not_active Expired - Fee Related
- 2020-02-20 PH PH1/2021/552018A patent/PH12021552018A1/en unknown
- 2020-02-21 TW TW109105620A patent/TW202045495A/zh unknown
- 2020-02-21 UY UY0001038592A patent/UY38592A/es unknown
-
2021
- 2021-08-17 IL IL285675A patent/IL285675A/en unknown
- 2021-08-18 JO JOP/2021/0227A patent/JOP20210227A1/ar unknown
- 2021-09-14 EC ECSENADI202167828A patent/ECSP21067828A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6608812B2 (ja) | Ezh2阻害のための塩酸塩形 | |
| KR101612642B1 (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
| JP5520301B2 (ja) | 強力なhcv阻害剤である2−チアゾリル−4−キノリニル−オキシ誘導体の結晶形態 | |
| JP2023511105A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536960A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512942A5 (cg-RX-API-DMAC7.html) | ||
| CN104010636B (zh) | 三环化合物、包含它们的组合物及其用途 | |
| US20090093495A1 (en) | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases | |
| CN108290824B (zh) | 索拉贝隆两性离子及其应用 | |
| JP2016128414A (ja) | ピリミジン誘導体の製造プロセス | |
| JP2023541434A5 (cg-RX-API-DMAC7.html) | ||
| JP2010505930A5 (cg-RX-API-DMAC7.html) | ||
| JP2016106102A (ja) | (3r,6r)−3−(2,3−ジヒドロ−1h−インデン−2−イル)−1−[(1r)−1−(2,6−ジメチル−3−ピリジニル)−2−(4−モルホリニル)−2−オキソエチル]−6−[(1s)−1−メチルプロピル]−2,5−ピペラジンジオンの新規結晶性形態 | |
| US20250361218A1 (en) | Agents and methods for treating dysproliferative diseases | |
| JP2016505071A5 (cg-RX-API-DMAC7.html) | ||
| JP2022535870A (ja) | Cdk9阻害剤の結晶多形体及びその製造方法と用途 | |
| JP2022523368A (ja) | 1-(1-オキソ-1,2-ジヒドロイソキノリン-5-イル)-5-(トリフルオロメチル)-n-[2-(トリフルオロメチル)ピリジン-4-イル]-1h-ピラゾール-4-カルボキサミド一水和物の結晶形態 | |
| JP2005529933A (ja) | キサンチンホスホジエステラーゼvインヒビター多形体 | |
| JP2022535850A5 (cg-RX-API-DMAC7.html) | ||
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| KR20130141712A (ko) | 이마티니브 메실레이트의 f, g, h, i 및 k 결정형 | |
| TW202245746A (zh) | N-((r)-2,3-二羥基丙氧基)—3,4—二氟—2—(2—氟—4—碘—苯基胺基)—苯甲醯胺之基本上純的形式iv之組合物及其用途 | |
| JPH11209284A (ja) | 骨形成促進剤 | |
| JP2024529533A5 (cg-RX-API-DMAC7.html) | ||
| US6420410B1 (en) | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |